Industries > Pharma > Global Erythropoietin Market Forecast 2017-2027

Global Erythropoietin Market Forecast 2017-2027

Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, Biosimilars, EPO API Manufacturing

PUBLISHED: 28 April 2017
PAGES: 164
PRODUCT CODE: PHA0187
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0187 Categories: , Tags: ,

The global erythropoietin market is expected to grow at a CAGR of 7.8% in the first half of the forecast period and CAGR of 4.8% in the second half of the forecast period. The market is estimated at $7.9bn in 2016 and $16.5bn in 2027.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 164-page report you will receive 84 tables and 93 figures – all unavailable elsewhere.

The 164-page report provides clear detailed insight into the global erythropoietin market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Erythropoietin Market forecasts from 2017-2027

• Revenue forecasts of global erythropoietin market, segmented by product type:
– Epoetin Alfa
– Epoetin Beta
– Darbepoetin Alfa
– Biosimilars
– Others

This section also discusses the leading drugs as well as SWOT analysis of each submarket.

• Revenue forecasts of global erythropoietin market, segmented by application:
– Anemia (Cancer and HIV Treatment)
– Kidney Disorders (ESRD and Dialysis)
– Others

• Revenue forecasts of global erythropoietin API manufacturing market, segmented by contract manufacturing and in-house manufacturing

• Erythropoietin Leading Regional Market forecasts from 2017-2027 covering North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.

Global Erythropoietin Market Forecast 2017-2027

Forecast for each regional market is further segmented by product type, application and country:
– US
– Canada
– UK
– Germany
– France
– Spain
– Italy
– Rest of Europe
– China
– Japan
– India
– Rest of Asia-Pacific
– Brazil
– Mexico
– Rest of Latin America
– Saudi Arabia
– South Africa
– Rest of Middle East and Africa

• Assessment of selected leading companies that hold major market shares in the erythropoietin market:
– Amgen
– Johnson & Johnson
– Roche
– Biocon
– 3SBio
– Pfizer
– Kyowa Hakko Kirin Co Ltd
– LG Life Sciences Limited
– Intas Pharmaceuticals Ltd
– Novartis AG

Visiongain’s study is intended for anyone requiring commercial analyses for the erythropoietin market. You find data, trends and predictions.

Buy our report today Global Erythropoietin Market Forecast 2017-2027: Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, Biosimilars, EPO API Manufacturing.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Erythropoietin Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Erythropoietin Market Forecast 2017-2027


Latest Pharma news

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

READ

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

READ

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

READ

Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021

READ

Categories

Category